Parathyroid hormone as a therapeutic agent.
Recent advances in the use of parathyroid hormone as a therapeutic agent include a controlled trial that assessed vertebral and non-vertebral fracture risk reduction in women, trials in men, and assessment of treatment on cortical and trabecular bone structure. The occurrence of osteosarcoma in long-term toxicology studies in rats is briefly reviewed.
Mitlak
Bruce H
BH
Medical Advisor, Eli Lilly and Company Lilly Corporate Center, Indianapolis, IN 46285, USA. b.mitlak@lilly.com
D000818:Animals; D001842:Bone and Bones / Q000187:drug effects / Q000502:physiology; D002986:Clinical Trials as Topic; D050723:Fractures, Bone / Q000517:prevention & control; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy* / Q000378:metabolism; D012516:Osteosarcoma / Q000139:chemically induced; D010281:Parathyroid Hormone / Q000009:adverse effects / Q000627:therapeutic use*
D010281:Parathyroid Hormone